Ascendis Pharma A/S vs Huntington Ingalls Industries Inc — how do they compare? Ascendis Pharma A/S trades at $256.14 (market cap $16.67B), while Huntington Ingalls Industries Inc trades at $329.05 (market cap $12.92B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays a 1.68% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HII | |
|---|---|---|
Market Cap | $16.67B | $12.92B |
Sector | Health | Technology |
52-Week High | $277.18 | $453.73 |
52-Week Low | $189.74 | $265.40 |
Enterprise Value | $17.04B | $15.84B |
Dividend Yield | — | 1.68% |
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
HII trades at $328.43, down 0.72% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Recent news includes a $2.2 billion contract award for surveillance and intelligence capabilities, enhancing its defense portfolio. Valuation ratios show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.
Outlook is positive due to contract wins and operational improvements, but risks include political headwinds and execution challenges. Analyst consensus price target is $359.67, suggesting 9.5% upside. Investment opportunity lies in margin expansion from submarine contracts, while monitoring defense budget volatility is key.
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →